Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
IPO Year: 2021
Exchange: NASDAQ
Website: nyxoah.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2023 | Buy | H.C. Wainwright | |
| 7/19/2023 | Neutral | Robert W. Baird | |
| 4/21/2022 | $30.00 | Outperform | Oppenheimer |
| 4/6/2022 | $21.00 | Peer Perform | Wolfe Research |
| 12/21/2021 | $47.00 | Overweight | Cantor Fitzgerald |
| 7/28/2021 | $43.00 | Overweight | Cantor Fitzgerald |
| 7/28/2021 | $40.00 | Overweight | Piper Sandler |
| 7/27/2021 | $43.00 | Buy | Stifel |
Fastest customizable press release news feed in the world
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 2025 Wells Fargo Healthcare ConferenceSeptember 3rd – Boston, MA Cantor Global Healthcare Conference 2025 September 4th – New York, NYFireside Chat: 11:30-12:00 pm ETWebcast: Cantor Fireside Chat Webcast Morgan Stanley 23rd Annual Global Healthcare Conference September 9th – New York, NY Presentatio
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 29, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,449,871.98 Total number of securities carrying voting rights: 37,544,782 (all ordinary shares) Total number of voting rights (= denominator): 37,544,782 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,775,566 (all granted subscription r
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to sever
INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep ApneaU.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,432,066.28 Total number of securities carrying voting rights: 37,441,140 (all ordinary shares) Total number of voting rights (= denominator): 37,441,140 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,793,941 (all granted subscription rig
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx
Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents comprehensive 12-month safety and efficacy results that supported the Company's PMA submission to the FDA. The peer-reviewed publication provides detailed analysis of the Genio® system's performance acros
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 27, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,431,121.38 Total number of securities carrying voting rights: 37,435,640 (all ordinary shares) Total number of voting rights (= denominator): 37,435,640 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,822,816 (all granted subscription rig
REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Wednesday, July 2, 2025 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. The Company will also set up a video conference to allow holders of securities of the Company who have duly registered
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy
Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral
Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00
Wolfe Research initiated coverage of Nyxoah S.A. with a rating of Peer Perform and set a new price target of $21.00
Cantor Fitzgerald resumed coverage of Nyxoah S.A. with a rating of Overweight and set a new price target of $47.00
Cantor Fitzgerald initiated coverage of Nyxoah with a rating of Overweight and set a new price target of $43.00
Piper Sandler initiated coverage of Nyxoah with a rating of Overweight and set a new price target of $40.00
Stifel initiated coverage of Nyxoah with a rating of Buy and set a new price target of $43.00
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
6-K - Nyxoah SA (0001857190) (Filer)
This live feed shows all institutional transactions in real time.
SC 13D/A - Nyxoah SA (0001857190) (Subject)
SC 13D/A - Nyxoah SA (0001857190) (Subject)
SC 13G/A - Nyxoah SA (0001857190) (Subject)
SC 13G/A - Nyxoah SA (0001857190) (Subject)
SC 13G/A - Nyxoah SA (0001857190) (Subject)
SC 13G - Nyxoah SA (0001857190) (Subject)
SC 13D/A - Nyxoah SA (0001857190) (Subject)
SC 13G - Nyxoah SA (0001857190) (Subject)
SC 13G - Nyxoah SA (0001857190) (Subject)
SC 13G - Nyxoah SA (0001857190) (Subject)
Live Leadership Updates
Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by
Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device
Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer. Christoph will oversee commercial activities globally, be responsible for sales and marketing in existing markets, and new market development. Christoph brings a wealth of experience in medical technologies to Nyxoah. He spent over 20 years with Johnson & Johnso
Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors Mont-Saint-Guibert, Belgium – January 9, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Mr. Daniel Wildman as an Independent Director to its Board of Directors*. Mr. Wildman is a 40-year veteran of the medical device industry. He is currently the Chairman of the Board of Progenerative Medical, Inc. and a Strategic Advisor to several medical device and pharmaceutical companies. He also serves as member of
Nyxoah appoints new CFO Mont-Saint-Guibert, Belgium – November 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in Finance across various geographies. Prior to GSK, Loïc built his career at EY and PwC. Loïc holds an executive master in Finance. He will replace current CFO, Fabian Suarez, who will leave Nyxoah at the end of 2021 to pursue a new opportunity as CE
Nyxoah Appoints Rita Johnson-Mills to its Board of Directors Mont-Saint-Guibert, Belgium – August 27, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Rita Johnson-Mills as an Independent Director to its Board of Directors. Robert Taub, Chairman of the Board of Directors of Nyxoah, commented: "We are delighted to welcome Rita Johnson-Mills to the Nyxoah Board of Directors. Her wealth of knowledge, extensive operating experience and expertise
Live finance-specific insights
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to sever
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Received an FDA Approvable Letter indicating the FDA wil
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024. Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred rev
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxo
REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating ResultsFDA approval on track for first quarter 2025, U.S. commercial team build out in progressCompany fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2024. Recent Financial and Operating Highlights Presented compelling DREAM data results at International
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations p
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating ResultsFDA regulatory submission complete, U.S. approval on track for end of 2024U.S. commercial launch fully funded with over €85 million in new capital raised Mont-Saint-Guibert, Belgium – August 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2024. Recent Financial and Operating Highlights Submitted final